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ABSTRACT
Objective: To compare consistency of adverse drug
reaction (ADR) data in publicly available product
information documents for brand drugs, between the
USA and Europe. To assess the usefulness of
information for prescribers and patients.
Design: A comparison review of product information
documents for antidepressants and anticonvulsants
concurrently marketed by the same pharmaceutical
company in the USA and Europe.
Setting: For each drug, data were extracted from the
US Product Inserts and the European Summary of
Product Characteristics documents between 09/2013
and 01/2015.
Participants: Individuals contributing ADR
information to product information documents.
Main outcomes measures: All ADRs reported in
product information sections 5 and 6 (USA), and 4·4
and 4·8 (Europe).
Results: Twelve brand drugs—24 paired documents
—were included. On average, there were 77 more
ADRs reported in the USA compared with in the
European product information document, with a
median number of 201 ADRs (range: 65–425) and 114
(range: 56–265), respectively. More product
information documents in the USA reported
information on the source of evidence (10 vs 5) and
risk (9 vs 5) for greater than 80% of ADRs included in
the document. There was negligible information
included regarding duration, severity, reversibility or
recurrence of ADRs. On average, only 29% of ADR
terms were reported in both paired documents.
Conclusions: Product information documents
contained a large number of ADRs, but lacked
contextual data and information important to patients
and prescribers, such as duration, severity and
reversibility. The ADR profile was found to be
inconsistently reported between the USA and Europe,
for the same drug. Identifying, selecting, summarising
and presenting multidimensional harm data should be
underpinned by practical evidence-based guidelines. In
order for prescribers to provide considered risk-benefit
advice across competing drug therapies to patients,
they need access to comprehensible and reliable ADR
information.
INTRODUCTION
Prescribing choice between several available
drug therapies is based on clinical efﬁcacy
with consideration given to the ‘perceived
risk’ of the drug. The perceived risk plays an
increasingly important role in treatment
decisions when there is little difference in
efﬁcacy or when comparative effectiveness
among competing treatments is unknown.
Robust information on the drug harm
proﬁle is therefore vital to facilitate the
informed risk-beneﬁt decisions made by
patients and prescribers.
Drug harm proﬁles are established from
various sources. Spontaneous reports of sus-
pected adverse drug reactions (ADRs) rely
on healthcare workers or patients recognis-
ing an association between a drug and an
adverse event (AE). Observational studies
and electronic healthcare records can be
Strengths and limitations of this study
▪ A paired review allowed for a perfect comparison
to examine adverse drug reaction profiles
between the USA and Europe.
▪ Adverse drug reaction data and document level
data were extracted in duplicate.
▪ The degree of inconsistency between adverse
drug reaction profiles, and lack of contextual
information found in antidepressant and anticon-
vulsant drug documents, may not be representa-
tive of other therapeutic areas.
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useful for identifying rare ADRs due to large sample
sizes, but they are subject to a number of biases and
often have no robust comparator.
Clinical trials have the potential to provide unbiased
estimates of harm outcomes, but typical sample sizes
result in uncommon ADRs remaining undetected.
Comprehensive information on drug harm in clinical
trials is now routinely collected as a result of improved
regulation since the early 1990s. Extensive research has
demonstrated that the collection and reporting of harm
data in peer-reviewed published clinical trials are both
still substandard and, as a consequence, the data are not
adequate to inform risk-beneﬁt decisions nor sufﬁcient
to contribute to cost-effectiveness analysis.1–3 The main
reasons for this are differing approaches in data collec-
tion, inadequate reporting of methodological details
and selective harm outcome reporting. Poor quality
harm data found in our systematic review of randomised
trials for neuropathic pain led us to investigate other
potential reliable sources of harm information.4 The
regulatory application for marketing authorisation
requires drug manufacturers to list all known drug harm
in a ‘product information document’ that is primarily
written for use by healthcare workers.5 6 The aim of this
regularly updated document is to present a comprehen-
sive picture, combining data from all available sources,
of the harm proﬁle gathered throughout the develop-
ment, testing and use of the drug. The document
should include any known harm discovered by manufac-
turers, who are the marketing authorisation holders, as
well as external parties. Consequently, this publically
available document is uniquely placed to be an invalu-
able source of information for patients, healthcare
workers, researchers and regulators. This document is
called the ‘summary of product characteristics’ (SmPC),
and is approved by the European Medicines Agency
(EMA); and the US product insert (USPI) is approved
by the US Food and Drug Administration (FDA).5 6
Previous research has demonstrated inconsistencies in
information included in the product documents. Studies
have reported discrepancies across countries for drugs
marketed by the same pharmaceutical company regard-
ing the number of ADRs, and differing risk estimates
and number of patients in the safety sample.7–9 Other
studies have found inconsistencies for the updating of
contraindication labelling, pregnancy and lactation
labelling, and advice on overdose in SmPCs compared
to clinical management.10–12
The aim of our review was to examine the usefulness
and relevance of ADR information—for antidepressants
and anticonvulsants—contained in product information
for prescribers and patients. We compared the content
between the USA and Europe for drugs marketed in
both regions by the same market authorisation holder,
to assess consistency. While some variability would be
anticipated due to differences in regulatory cycles
between regions and construction of the documents by
different company teams, we would expect that the ADR
proﬁle between paired documents would be similar, as it
should be based on centralised safety data.
METHODS
This review involved antidepressant and anticonvulsant
brand drugs identiﬁed in a previous systematic review of
randomised control trials evaluating treatments of post-
herpetic neuralgia and painful diabetic neuropathy.4
The brand drugs included were those, concurrently mar-
keted in the USA and Europe, with available product
information documents (USPI and SmPC).
Documents were downloaded from September 2013–
January 2015 from the US FDA and EMA, respect-
ively.13–15 The paired documents were chosen to ensure
inclusion of the same dose and formulation, and down-
loaded at the same time.
Data were extracted from sections 5 and 6 in the USPI
and sections 4·4 and 4·8 in the SmPC.
Regulatory guidelines from the FDA and EMA request
that the manufacturers should report all ADRs, which
are AEs where there is a reasonable possibility the drug
has played a causal role, however, documents sometimes
included the term ‘adverse event’ for which the accepted
deﬁnition implies that the drug may not be causal.5 6 As
it was often not clear whether the events were truly ADRs
or AEs, a pragmatic decision to extract all harm events
reported was made—hereafter referred to as ADRs.
Justiﬁcation for this decision was based on the guidance
by the EMA, which speciﬁes that ‘adverse events, without
at least a suspected causal relationship should not be
reported’ and the FDA guidance, which stated (report-
ing of) ‘an adverse reaction not plausibly related to drug
therapy should be avoided’. A summary of the reporting
guidelines for the FDA and European Commission can
be seen in online supplementary table A.
Data extracted included: all ADRs; risk estimates; study
design; sample size; the criterion used to identify ADRs
from all AEs recorded in a clinical trial; dictionary used
for coding ADRs, whether information on recurrent
ADRs was reported; information on onset and duration
of ADRs. Document level data were extracted by three
reviewers (KL, VRC and OS) in duplicate, using a custo-
mised and piloted spreadsheet. Any differences in inter-
pretation were resolved through discussion. Information
on individual ADR terms was extracted electronically
into a spreadsheet by a single reviewer (KL) and then
checked by a second reviewer (VRC). Duplicate ADRs
within a document were removed and the greater risk
estimate was kept. ADRs due to rapid withdrawal or
interactions with other medications were excluded from
the review.
As this is a descriptive study, appropriate measures of
central tendency (mean, median) and dispersion (SD,
range) were calculated for quantitative data, frequency
and percentages for categorical variables. No signiﬁ-
cance tests were performed. The study protocol is avail-
able on request from the corresponding author.
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RESULTS
Nineteen anticonvulsant and antidepressant brand
drugs were included as contenders for this review.
Twelve of these were found to be concurrently marketed
in Europe and the USA, with SmPC and USPI documen-
tation available. The characteristics of the documents for
the included drugs are listed in table 1 and all drugs
identiﬁed from our previous review are listed in online
supplementary table B.
On average, 77 more ADRs were reported in the US
documents than in the European documents. The
median numbers of ADRs were 114 (IQR 93, 150) and
201 (IQR 114, 262) in the European and US documents,
respectively (table 2). The majority of the ADRs terms
differed between documents, on average only 29% of
the total number of ADRs were reported in both docu-
ments (table 3).
Source of evidence
Knowing the source of the evidence of the ADR report
(clinical trial, observational study, spontaneous report)
provides important contextual information as both the
study design and data collection method will directly
impact on the estimated risk of the ADR.16 17 The
source of the ADR report was speciﬁed more frequently
in the US documents than in the European documents.
Of the 24 documents ten US and ﬁve European docu-
ments reported the source of the ADR report for 80%
or more of all ADRs listed in the document, and the
majority were reported as originating from clinical trial
data (table 2 and online supplementary table C).
Risk of an adverse drug reaction
It is not possible to accurately estimate the risk of ADRs
identiﬁed through spontaneous reports as the number
of people who prescribed the drug is unknown. Crude
estimates can sometimes be sought from sales or elec-
tronic health record data and can be used to calculate
an approximate risk.18 The European Commission guid-
ance recommends that this estimate be based on
‘adequately designed study’ data, and with zero events
observed, suggests estimating the upper 95% CI limit
using 3/X, where X represents the total sample size
summed up across all relevant clinical trials and studies
(see online supplementary table A). It was unclear
for all documents how risks of ADRs originating from
spontaneous reports were derived. Nine of 12 US and
5 of 12 European documents reported risks for 80%
or more of all ADRs originating from clinical trials
(table 2).
Observation time
The causal mechanism of an ADR is often time depend-
ent and the absolute risk will depend on the duration of
exposure, therefore, information on the observation
period is necessary for interpretation. Knowledge of the
observation period also reveals how much is known about
long-term use of the drug. Eight US and one European
Table 1 Characteristics of drug product information documents
Drug Brand name Company
Document
origin Formulation Dose (mg)
Date of
document
Carbamazepine Tegretol Novartis Europe Tablets 100 07/06/2013
USA Tablets/chewable tablets/
suspension
100–400 15/02/2013
Gabapentin Neurontin Pfizer Europe Hard capsules 300 03/04/2013
USA Capsules/tablets/suspension 100–800 01/05/2013
Lamotrigine Lamictal GlaxoSmithKline Europe Dispersible/chewable 200 01/02/2013
USA Dispersible/chewable 25–200 07/23/2012
Oxcarbazepine Trileptal Novartis Europe Tablets 150 17/04/2013
USA Tablets/oral suspension 150–600 02/07/2013
Pregabalin Lyrica Pfizer Europe Hard capsules 25 04/12/2013
USA Capsules 25–300 01/06/2013
Topiramate Topamax Janssen Europe Tablet 100 03/06/2013
USA Tablet/sprinkle capsules 25–200 01/10/2012
Zonisamide Zonegran Eisai Europe Hard capsules 25–100 13/02/2014
USA Capsules 25–100 24/01/2012
Clomipramine Anafranil Novartis Europe Capsules 50 10/07/2012
USA Capsules 25–75 26/10/2012
Duloxetine Cymbalta Eli Lilly Europe Capsules 30–60 15/07/2013
USA Capsules 20–60 01/10/2012
Fluoxetine Prozac Eli Lilly Europe Hard capsules 20 01/03/2013
USA Capsules 10–90 01/07/2014
Venlafaxine Efexor/Effexor Pfizer Europe Capsules 75–100 26/01/2015
USA Capsules 37.5–150 01/12/2014
Phenytoin Epanutin/Dilantin Pfizer Europe Oral suspensions/tablets 30–100 04/01/2013
USA Capsules/tablets 30–100 07/03/2014
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document contained information on the duration of the
observation period for a couple of ADRs (see online sup-
plementary table C) but only three documents from the
USA reported this information for the majority of the
ADRs arising from clinical trials (table 2).
Duration, severity, recurrence and reversibility of an ADR
The anticipated duration, severity and likelihood of
recurrence of an ADR is important to patients and pre-
scribers. Only one US document contained any informa-
tion about duration of an ADR, four US documents
Table 2 Summary of data reported by product information document
Europe USA
Item Median (IQR) Median (IQR)
Adverse Drug Reaction Number ADRs 114 (93, 150) 201 (114, 262)
Data source of ADR report (1) Clinical trial 3 (1, 84) 172 (58, 256)
(2) Spontaneous report/other 4 (1, 9) 8 (2, 14)
(3) Unspecified 88 (1, 112) 9 (1, 35)
Document level reporting n (%) n (%)
Documents reporting items for >80% of clinical
trial ADRs
(1) Number of participants 2 (17) 8 (66)
(2) Risk estimates 5 (41) 9 (75)
(3) Risk estimates by severity 0 (0) 1 (8)
(4) Length of study 0 (0) 3 (25)
Is any information on ADR risk reported by: (1) Indication (yes) 2 (17) 9 (75)
(2) Dose (yes) 0 (0) 4 (33)
Did the document contain any information on: (1) Recurrent ADRs (yes) 0 (0) 0 (0)
(2) Duration of ADR (yes) 0 (0) 1 (8)
ADRs, adverse drug reactions; IQR, Interquartile range.
Table 3 Reporting of adverse drug reactions (ADR) by product information document and drug
Europe Proportion with
same ADR termDrug USA Reported Not reported
Carbamazepine Reported 75 89 0.36
Not reported 47 –
Gabapentin Reported 89 28 0.20
Not reported 336 –
Lamotrigine Reported 36 20 0.14
Not reported 205 –
Oxcarbazepine Reported 47 42 0.18
Not reported 168 –
Pregabablin Reported 88 91 0.24
Not reported 187 –
Topiramate Reported 84 181 0.20
Not reported 164 –
Zonisamide Reported 39 58 0.16
Not reported 147 –
Clomipramine Reported 53 43 0.14
Not reported 272 –
Duloxetine Reported 104 32 0.60
Not reported 37 –
Fluoxetine Reported 50 61 0.32
Not reported 45 –
Epanutin Reported 50 36 0.50
Not reported 15 –
Efexor Reported 68 58 0.42
Not reported 37 –
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presented some information on severity but the informa-
tion was limited to only a few ADRs. None of the docu-
ments presented data regarding recurrence or
reversibility (table 2).
Identifying ADRs from AEs reports collected from clinical
trials
In clinical trials, many AEs will be recorded for each
treatment and not all of these will be causally linked to
the drug under investigation. Ideally, a signal detection
method that is statistically underpinned should be used
to ﬂag signals of ADRs from all AEs reported in a clin-
ical trial. None of the documents used a statistical
method to ﬂag a signal but nine US and three
European documents reported the rule-based approach
used. It is important to know what method has been
applied as this will dictate the number and type of ADRs
that are ﬂagged. The full list of differing rule-based
approaches used are reported in table 4. It can be seen
that rule-based methods were not the same in three
paired documents and that seven US documents used
multiple criteria that were used within the same docu-
ment (table 4).
Dictionary for coding AEs
Medical terminology dictionaries are used to code AE
terms with an aim to standardise reports. For only one
drug was the dictionary used reported in both docu-
ments, and it was different in each (see online supple-
mentary table D). Six US and three European
documents speciﬁed the dictionary used.
DISCUSSION
One of the aims of the FDA and EMA guidance for
developing product information documents is to
promote the consistency of harm reporting across drugs.
It would be expected that the harm proﬁles of a drug
marketed by the same company should be similar in the
US and European document with the only differences
due to variability in regulatory recommendations. This
study has identiﬁed a lack of consistency across paired
documents in the number and type of harms reported,
approaches to code harm terms and the availability of
contextual information required for interpretation. Our
results are in line with other studies that found a high
number of discrepancies in ADRs between the USA and
Europe across a range of differing therapeutic areas.7–9
Table 4 Rule-based criteria listed in documents, for selecting adverse reactions to report in document from all adverse
events collected during a clinical trial
Drug Document No Criteria listed*
Gabapentin USA 1 All AEs except those too general to be informative OR not reasonably associated with the
use of drug
Lamotrigine USA 1 AEs from RCT except AEs that are too general to be informative or not reasonably
attributed to the drug
USA 2 AEs from RCT that were >5% AND greater than placebo arm
USA 3 AEs from RCT with frequency between 2–5% AND greater than placebo arm
Oxcarbazepine Europe 1 AEs that were clinically meaningful post marketing reports
USA 1 AEs from RCT that were ≥2% AND the incidence was greater than placebo
Pregabablin Europe 1 All AEs that occurred at an incidence greater than placebo and in more than one patient
USA 1 AEs from RCT that were ≥1% AND at least numerically more than in the placebo group
USA 2 AEs from RCT that were ≥2% AND the AE in higher dose group that was ≥2% the rate in
both the placebo and low dose groups
Topiramate USA 1 AEs from RCT that were ≥2% AND the incidence was greater than placebo
USA 2 AEs from RCT that were ≥1% AND the incidence was greater than placebo
USA 3 All AEs except those too general to be informative OR those not reasonably associated
with the use of drug
Zonisamide USA 1 All events included except those too general to be informative, trivial events or those not
reasonably thought to be associated with drug
USA 2 AEs from RCT that were ≥2% AND the incidence was greater than placebo
Clomipramine USA 1 Commonly observed AEs associated with the drug and not seen at an equivalent
incidence among placebo treated patients
USA 2 AEs leading to discontinuation
Duloxetine Europe 1 Most common AEs reported
USA 1 AEs from RCT that were ≥5% AND twice the placebo rate
USA 2 AEs from RCT that were ≥2% in RCT
USA 3 AEs from RCT that were ≥5% in RCT
Fluoxetine USA 1 AEs from RCT that were >5% AND at least 2 times greater than placebo
USA 2 AEs from RCT that were ≥2% AND the incidence was greater than placebo
*Criteria are from 9/12 documents from the USA and 3/12 from Europe, the other documents did not report any criteria by which the harms
were selected for reporting in the document.
AEs, adverse events; RCT, randomised controlled trial.
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The lack of consistency could be in part due to differing
rule-based arbitrary criteria used to identify ADRs from
all AEs reported in a trial as these criteria even varied
within a document. It was not possible for us to assess
whether the trials contributing to both paired documents
were identical, potentially adding further discrepancies.
It is possible that the year of approval may be associated
with lack of consistency; however, with only a few drugs
included and low consistency across all drugs, we did not
explore this aspect, but previous studies have examined
this and found conﬂicting results. Eriksson et al7 reported
that drugs approved after 2000 showed higher consist-
ency, but Kesselheim et al8 reported that length of time
on the market was not associated with consistency.
The lack of consistency demonstrated in this study
across matched drug documents raises questions as to
whether information across a class of drugs produced by
different manufacturers could ever be usefully com-
pared. Despite this, risk-beneﬁt comparisons, in which
these documents play a fundamental role in informing
prescribers knowledge of harm, are undertaken daily.
The differences in the number of ADRs found
between paired documents of the same drug may not all
be real differences in the harm proﬁle, but could simply
be differences in ADR coding and presentation. It has
been shown that ADR summaries are dependent on the
dictionary used and even when the same dictionary is
used there is inter-observer variation due to coding con-
ventions.19–21 With differing dictionaries used to code
harm, data aggregated to different levels and lack of pro-
cedures reported, it was not possible for us to draw
further conclusions within this study.
In general, the US documents contained more infor-
mation on methodological aspects and contextual infor-
mation needed to assess and interpret harm events, such
as data source of ADR and information by indication.
However, the additional volume of material made the
overall harm proﬁle harder to absorb than information
in the European documents. This contrasting approach
of reporting ADRs in either insufﬁcient or excessive
detail has previously been raised by Kesselheim et al.8
The guidance from the EMA and FDA state that harm
information should be ‘clear and readily accessible’.5 6
Better ways to prioritise and present harm data are
required to enable patients and prescribers to undertake
informed risk-beneﬁt decisions.
Current clinical practice may often be too reliant on
prescribers drawing on personal experience, knowledge
from a colleague or abbreviated ADR summaries avail-
able in prescribing handbooks. Most of the product docu-
ments included in this review reported more than 100
ADRs, with one document listing over 400. Studies in dif-
ferent therapeutic areas have also reported similar high
numbers, with Kesselheim et al8 reporting a median of
105 ADRs for 20 top-selling drugs across four countries,
Eriksson et al7 reporting 4003 ADRs in 40 drugs across
two countries, and Duke et al22 reporting a median of 49
ADRs across 5602 drugs and 10% having greater than 150
ADRs reported. With such large numbers of ADRs
reported and no information provided on severity, dur-
ation or recurrence, it is questionable how useful the
information in these documents is. In general, the US
documents contained a larger number of ADRs and it
was often unclear if these harm events were truly ADRs
rather than AEs. It is possible that the over-inclusion of
many AEs is made to minimise the risk of litigation since
the manufacturers of the brand drug are held legally
responsible if these are not reported.23 However, the over-
inclusion of AEs will make the absorption of pertinent
harm information harder for prescribers and patients.
More rigorous guidance underpinned by empirical evi-
dence is needed to reduce current uncertainty around
what ADR information should be included and how it
should be summarised and presented.
The wide risk categories predominantly used in the
European documents should be reviewed. Adverse reac-
tions are placed into categories such as ‘very common’
(>1/10) or ‘common’ (>1/100 and <1/10). While the
purpose of these risk categories may be to assist readers
in assimilating a large volume of harm information, they
are too vague to be useful for serious ADRs. ADRs such as
angle-closure glaucoma, rhabdomyolysis, ataxia and arth-
ralgia are categorised as ‘common’, implying the risk
could be anywhere from 1 in 100 to 1 in 10. It is difﬁcult
to see how such an estimate can be useful in informing a
risk-beneﬁt decision especially in the absence of any
information on severity, duration or reversibility. Instead,
it may be preferable, where possible, to provide point esti-
mates of risk with an indication of precision for life-
threatening events or events that signiﬁcantly impact a
patient’s quality of life. In contrast, wide risk categories
for ADRs with minimal impact on quality of life or phys-
ical health, such as ‘yawning’, may be sufﬁcient.
All antidepressant documents included a warning for
suicidal events with anticipated time to onset. No other
information regarding onset, duration or recurrence was
included for any other ADR. A patient may be willing to
risk the occurrence of tinnitus or peripheral vision loss
if the condition resolves but not if the duration is exces-
sive and recurring.
Current guidance for clinical trials in the published lit-
erature has existed since 2004,24 but has made little
impact on the quality of harm reporting.1–3 This present
review also found that data from trials were inadequately
summarised and reported, and, notably, differed across
paired documents of the same drug. Aagaard and
Hansen9 found that the sources of discrepancies across
documents were primarily from information based on
clinical trials.
Bringing together many sources of disparate informa-
tion from various locations is technically problematic. An
ambitious new initiative with the aim of collating informa-
tion from a variety of sources (spontaneous reports, pub-
lished literature, product documents and observational
data) has been launched, but it is still in its infancy and
its effectiveness is as yet unknown.25 There are initiatives
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to rank drugs for risk of a speciﬁc drug harm such as
drug-induced arrhythmias (http://www.CredibleMeds.
org, http://www.BrugadaDrugs.org), but these are
lacking an overall harm proﬁle. While the product infor-
mation document is written with a focus on providing
information to healthcare workers, we believe this publi-
cally available document is uniquely placed to be an
invaluable source of information for patients and
researchers. It is the only source that contains unpub-
lished evidence held by the pharmaceutical company
and includes all available evidence from clinical trials,
post-authorisation safety studies and spontaneous report-
ing. What ADRs should be included and how to usefully
present these multidimensional data to be informative to
patients and prescribers requires further consideration.
Several studies have reported that patients would like
more information on ‘side effects’, believing that full dis-
closure of side effect information would help them
make more informed treatment decisions.26 27 Many
studies have shown that giving patients more informa-
tion does not lead to an increase in the reporting of
‘side effects’.28 29 A recent review showed that patients
have a tendency to underestimate their risk of harm.30
But there is evidence that when patients have been pre-
sented with harm leaﬂets that lack numerical informa-
tion, they were more likely to overestimate their risk.31 32
It is a statutory requirement for all drug manufacturers
to include Patient Information Leaﬂets (PILs) as an
insert in the medicine package. A review of the effective-
ness of PILs found that patients thought them to be
poor quality in terms of layout and content, and consid-
ered that they did not help increase knowledge to allow
informed risk-beneﬁt decision-making.33
While it is clear that all serious and unexpected ADRs
should be reported, it is also important to know the true
risk of common and anticipated ADRs, as they have cost-
beneﬁt consequences and can signiﬁcantly impact on a
patient’s quality of life. In a trial, many hundreds of AEs
may be recorded and a decision of what should be
reported has to be made. Currently, common harm out-
comes are usually selected by means of an arbitrary rule-
based criterion such as ‘an AE that occurs in at least 2%
of patients and is twice the placebo rate’. Using this type
of criterion leads to ﬂagging the most frequent but not
necessarily the most important ADRs from a patient or
healthcare provider perspective.
It has previously been proposed that consistency in
harm information from trials in the published literature
could be improved by developing a set of ‘core out-
comes’ to be reported by drug class based on the prin-
ciple proposed for effectiveness studies (http://www.
comet-initiative.org).2 These ‘core outcome sets’ are the
agreed minimum outcomes that should be reported, and
are developed through a consensus process that includes
all key stakeholders. A particularly common issue pertin-
ent to harm proﬁles concerns the absence of informa-
tion for a particular harm. It can never be clear whether
this is simply because it was not reported (below the
threshold of a rule-based criterion) or no events were
observed. To reduce the inconsistency demonstrated in
this review, we would endorse development of core
‘harm’ outcome sets by drug class to be reported in add-
ition to all serious and unexpected ADRs.
How harm data are collected has an important impact
on the type and the number of events recorded.17 24
While we have not speciﬁcally explored this issue in the
present study, it is clearly vital, and more attention should
be paid to methods used to collect and record AEs.
This review highlights a number of weaknesses in
harm information contained in product descriptions
Figure 1 Overview of issues to address in selection and presentation of harm information from clinical studies. ADRs, adverse
drug reaction; AEs, adverse event; QoL, quality of life; RCT, randomised controlled trial; SARs, serious adverse reaction;
SUSARs, suspected unexpected serious adverse reactions.
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that are also relevant to harm reporting in primary
studies. We propose a conceptual framework to address
these issues in ﬁgure 1.
CONCLUSIONS
Publically available drug product documents have the
potential to be valuable and vital sources of harm infor-
mation, but data included in these were found to be
inconsistent and not usefully presented. Identifying,
selecting, summarising and presenting multidimensional
harm data should be underpinned by practical evidence-
based guidelines. Prescribers and patients require reli-
able reporting of pertinent ADRs to enable them to
undertake meaningful informed risk-beneﬁt decisions
across competing drug therapies.
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